AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01930877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Normal saline bolus followed by infusion
Study NCT04486079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricia PreOp
Description: A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
Study NCT03891498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Description: The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
Study NCT01486511 — intervention group
Intervention type: PROCEDURE
Intervention: Liver resection
Description: Hepatectomy including both minor and major.
Study NCT01486511 — intervention group
Intervention type: RADIATION
Intervention: Computed Tomography
Description: Computed Tomography +/- pulmonary angiography
Study NCT02987322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: honey
Description: Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
Study NCT01829828 — intervention group
Intervention type: BEHAVIORAL
Intervention: No intervention
Description: This is an observational study with no investigational drug administered.
Study NCT00996359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Irradiated haploidentical allogeneic lymphocytes
Description: Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.
Study NCT00996359 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: 100 cGy TBI
Study NCT03321656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: 0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally
Study NCT03321656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus XR
Description: 0.07-0.14 mg/kg/day every morning orally
Study NCT02846597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained lung inflation in preterms (SLI).
Description: Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time
Study NCT02844348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis session
Study NCT03952728 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intensive lifestyle intervention
Description: Lifestyle intervention focused on weight loss through diet and physical activity
Study NCT03952728 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diabetes support and education
Description: Behavioral intervention focused on diabetes support and education
Study NCT06031870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal pessary
Description: In the pessary group, all patients received a cube pessary, which was individually adapted to each patient. These pessaries exist in sizes 0 (25 mm edge length) to 9 (75 mm edge length). Patients were instructed by a physician or a trained nurse on how to autonomously manage the pessary, including daily changing and cleaning. After one week of treatment, all patients had an office visit to check if fitting was correct and if autonomous handling of the pessary was feasible. Treatment duration was 12 weeks.
Study NCT06031870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care consisted of a pelvic floor group exercise course led by a midwife, a physiotherapist, or an osteopath. Courses were in general once a week for a minimum of seven to a maximum of twelve weeks. The course was chosen by the patient, and the study team had no influence on the choice.
Study NCT06031870 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Twelve pelvic floor physiotherapy sessions were prescribed by the study physician. Pelvic floor physiotherapy was performed in individual courses by trained physiotherapists. The patient was free to choose the physiotherapist and the study team had no influence on the choice.
Study NCT03807700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Denture Adhesive
Description: In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
Study NCT04237129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gan & Lee Insulin Aspart
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.
Study NCT02407132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted DSME
Description: Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
Study NCT02407132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard DSME
Description: Active Comparator: Standard DSME Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
Study NCT01264354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine 30mg
Description: Clevudine 30mg
Study NCT01264354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine 20mg+Adefovir dipivoxil 10mg
Description: Clevudine 20mg+ Adefovir 10mg
Study NCT01264354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine 20mg
Description: Clevudine 20mg
Study NCT03294421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined access tympanomastoidectomy
Description: Trans canal surgery with the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation allowing better visualization and removal of the cholesteatoma before mastoid debridement. In this surgery, mastoid debridement is conducted only if there was no full endoscopic removal of the cholesteatoma. The other procedures of this type of surgery are similar to the standard tympanomastoidectomy technique.
Study NCT03294421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard closed tympanomastoidectomy
Description: 1. Supine position and general anesthesia with orotracheal intubation~2. Antisepsis and placing of sterile fields~3. Local anesthesia of the external auditory canal with lidocaine 2% and adrenaline 1:100. 000 UI~4. Retroauricular incision~5. Removal of the temporal muscle fascia~6. Elevation of the surgical flap of the tympanic meatus~7. Visualization and exploration of the cholesteatoma~8. Exploration of the ossicular chain~9. Mastoid debridement~10. Conservation of the upper posterior wall of the auditory conduct~11. Removal of the cholesteatoma~12. Tympanoplasty with the temporal fascia~13. Retroauricular suture with vycril 3.0 and mononylon 4.0
Study NCT00432796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: 5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0
Study NCT00432796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patients will be randomized post-operative to receive either active treatment or placebo.~the placebo will be given as a subcutaneous injection once a day. the amount of the placebo will be equivalent to the active treatment depending on the type of surgery.~ie. 5,000 iu or 200 iu/kg
Study NCT03533881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arom Digest Slim
Description: Arom Digest Slim is a dietary supplement approved in Romania by SNPMAPS, with notification number AA 10802/2017.~It contains: hydrolyzed fish collagen (94,8 %) and volatile oils (5,2 %): Citrus paradisi (2,40 %), Citrus aurantifolia (1,24 %), Menta avensis (0,92 %), Cinamomum zeylanicum (0,56%) Patients take 4 grams of supplement per day; the supplement is dissolved in 750 ml water and drunk throughout the day
Study NCT03533881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional changes
Description: Education to increase the fruits and vegetables, decrease refined carbohydrates, decrease high fat animal products, regulation of meal programme, increase water intake to at least 1,5 liters per day
Study NCT03625310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride
Study NCT03625310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride with TCP
Study NCT03625310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride with CXP
Study NCT03625310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride with CPP-ACP
Study NCT03860714 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: We do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Clinical Dementia Rating(CDR),Quality of Recovery Score - 40 (QoR-40),Geriatric Depression Scale (GDS),CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
Study NCT03117894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 5 mg/ml, 35 ml
Description: Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.
Study NCT03117894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 50 microg/ml
Description: The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
Study NCT03117894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethason 4 mg
Description: Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.
Study NCT03117894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 1,5 g
Description: Administered preoperatively to prevent pain postoperatively.
Study NCT03117894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
Study NCT03117894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arcoxia, 120 mg
Description: Administered preoperatively to prevent pain postoperatively.
Study NCT03117894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 mg
Description: Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.
Study NCT03117894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.
Study NCT04066296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.
Study NCT02630849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intercostal muscle flap and pericostal no-compression suture
Description: intercostal muscle flap and pericostal no-compression suture of the intercostal space
Study NCT02630849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard suture technique of the intercostal space
Description: Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
Study NCT01553227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ventilator
Description: Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
Study NCT03440294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: resting standard spirometry
Description: The subject (seated, bust straightened) should perform, after a slow and maximum inspiration, a forced and complete exhalation followed by a new inspiration to the total lung capacity.
Study NCT03440294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: maximum exercise testing
Description: Incremental exercise on cycle ergometer with 100W start for men (80W for women) for 4 minutes as part of the warm-up. Then, step increment of a 50W power for men (40W for women) lasting 2 minutes each.
Study NCT02678000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHW090
Description: LHW090 is orally administered
Study NCT02678000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of LHW090
Study NCT00509379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
Study NCT00509379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
Study NCT03672461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Practice Program
Description: The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
Study NCT03672461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Conditioning Program
Description: The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants.
Study NCT01058486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management and Motivational Interviewing
Description: Post hospital discharge, patients will be referred (\<2 weeks) to pulmonary rehabilitation (PR) (1-2 sessions per week for 6-8 weeks). PR visits (approximately 1 hour) will include education, strengthening and endurance exercise as the patient tolerates.~A counselor (RN or RRT) and patient will meet once weekly after PR session. The counselor will assess the patient's self efficacy and knowledge of self-management principles of COPD. Based on the assessment and greatest needs identified by patient, the counselor will work with the participant to collaboratively develop a specific SM plan.Motivational interviewing techniques will be used.~Following completion of PR, the counselor will contact the patient monthly to provide clinical support on SM of COPD. To ensure consistency of intervention, we will use standardized treatment procedures and phone scripts.
Study NCT04220749 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Standard of Care: Radiation +/- Chemotherapy
Study NCT04220749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-Oral Surgery (TOS) + Neck Dissection
Description: Trans-Oral Surgery (TOS) + Neck Dissection (plus radiation, if required)
Study NCT04072991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary therapy
Description: participants will undertake a four week diet as part of their IBS treatment
Study NCT02566603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
Study NCT02566603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
Study NCT02566603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
Study NCT02566603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
Study NCT02566603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
Study NCT05135884 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard inpatient stroke rehabilitation
Description: According to Swiss national guidelines and local protocols
Study NCT02454075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YF476
Description: Gastrin receptor antagonist
Study NCT02638675 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness program
Description: All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
Study NCT02638675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness program
Description: All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
Study NCT02638675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
Study NCT02638675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
Study NCT02638675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
Study NCT03743129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg p.o, qd
Study NCT01408875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low electrical myostimulation
Description: The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
Study NCT02621047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive alectinib as per the dosage schedule mentioned in arm description.
Study NCT03495154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parietene DS Composite Mesh
Description: All subjects enrolled will receive the Parietene DS Composite Mesh
Study NCT01013623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: surgical resection to remove all known disease
Study NCT01013623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery plus 2 adjuvant doses of BCG
Description: Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.
Study NCT01013623 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: best medical therapy
Description: Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.